Under the terms of the amendment, the parties agreed to reduce the price of each share of Rite Aid common stock depending on the number of pharmacy stores Walgreens will divest to gain regulatory approval. The tentative agreement states Walgreens will divest up to 1,200 Rite Aid pharmacy stores, 200 more than the terms set in the original agreement.
If Walgreens divests 1,000 or fewer stores, the stock price will be set at $7 per share. If the pharmacy retailer divests 1,000 to 1,200 stores, the price per share will be prorated. If the company divests 1,200 stores or more, the stock price will lower to $6.50 per share. Under the original agreement, Walgreens had agreed to pay $9 per share, valuing the company at roughly $9.4 billion when the companies publicized the deal in October 2015, according to a Forbes report.
Both companies also agreed to extend the expiration date on the merger agreement from Jan. 27 to July 31 to allow both parties to obtain the necessary regulatory approvals.
More articles on transactions and valuations:
Report: Hospital mergers increase institution’s value, savings
This week’s 3 most-read transactions and valuations stories
Fitch: Healthcare organizations incentivized to merge with larger provider networks
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.